Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Advances in covalent kinase inhibitors.

Abdeldayem A, Raouf YS, Constantinescu SN, Moriggl R, Gunning PT.

Chem Soc Rev. 2020 Mar 30. doi: 10.1039/c9cs00720b. [Epub ahead of print] Review.

PMID:
32227030
2.

Corrigendum to High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype12 [Translational Oncology Volume 12, Issue 2, February 2019, Pages 256-268].

Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J.

Transl Oncol. 2020 Feb;13(2):490-492. doi: 10.1016/j.tranon.2019.08.001. No abstract available.

3.

Direct Targeting Options for STAT3 and STAT5 in Cancer.

Orlova A, Wagner C, de Araujo ED, Bajusz D, Neubauer HA, Herling M, Gunning PT, Keserű GM, Moriggl R.

Cancers (Basel). 2019 Dec 3;11(12). pii: E1930. doi: 10.3390/cancers11121930. Review.

4.

Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function.

Lercher A, Bhattacharya A, Popa AM, Caldera M, Schlapansky MF, Baazim H, Agerer B, Gürtl B, Kosack L, Májek P, Brunner JS, Vitko D, Pinter T, Genger JW, Orlova A, Pikor N, Reil D, Ozsvár-Kozma M, Kalinke U, Ludewig B, Moriggl R, Bennett KL, Menche J, Cheng PN, Schabbauer G, Trauner M, Klavins K, Bergthaler A.

Immunity. 2019 Dec 17;51(6):1074-1087.e9. doi: 10.1016/j.immuni.2019.10.014. Epub 2019 Nov 26.

5.

Structural Implications of STAT3 and STAT5 SH2 Domain Mutations.

de Araujo ED, Orlova A, Neubauer HA, Bajusz D, Seo HS, Dhe-Paganon S, Keserű GM, Moriggl R, Gunning PT.

Cancers (Basel). 2019 Nov 8;11(11). pii: E1757. doi: 10.3390/cancers11111757. Review.

6.

Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer.

Unterleuthner D, Neuhold P, Schwarz K, Janker L, Neuditschko B, Nivarthi H, Crncec I, Kramer N, Unger C, Hengstschläger M, Eferl R, Moriggl R, Sommergruber W, Gerner C, Dolznig H.

Angiogenesis. 2019 Oct 30. doi: 10.1007/s10456-019-09688-8. [Epub ahead of print]

PMID:
31667643
7.

The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis.

Orlova A, Neubauer HA, Moriggl R.

Haematologica. 2019 Oct;104(10):1907-1909. doi: 10.3324/haematol.2019.225862. No abstract available.

8.

JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.

Mohrherr J, Haber M, Breitenecker K, Aigner P, Moritsch S, Voronin V, Eferl R, Moriggl R, Stoiber D, Győrffy B, Brcic L, László V, Döme B, Moldvay J, Dezső K, Bilban M, Popper H, Moll HP, Casanova E.

Int J Cancer. 2019 Dec 15;145(12):3376-3388. doi: 10.1002/ijc.32624. Epub 2019 Sep 10.

9.

Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Pencik J, Pham HTT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DNT, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2019 Aug 13;10(8):605. doi: 10.1038/s41419-019-1853-1.

10.

STAT3β is a tumor suppressor in acute myeloid leukemia.

Aigner P, Mizutani T, Horvath J, Eder T, Heber S, Lind K, Just V, Moll HP, Yeroslaviz A, Fischer MJM, Kenner L, Győrffy B, Sill H, Grebien F, Moriggl R, Casanova E, Stoiber D.

Blood Adv. 2019 Jul 9;3(13):1989-2002. doi: 10.1182/bloodadvances.2018026385.

11.

STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice.

Boutillon F, Pigat N, Sala LS, Reyes-Gomez E, Moriggl R, Guidotti JE, Goffin V.

Cancers (Basel). 2019 Jul 2;11(7). pii: E929. doi: 10.3390/cancers11070929.

12.

Structural and functional consequences of the STAT5BN642H driver mutation.

de Araujo ED, Erdogan F, Neubauer HA, Meneksedag-Erol D, Manaswiyoungkul P, Eram MS, Seo HS, Qadree AK, Israelian J, Orlova A, Suske T, Pham HTT, Boersma A, Tangermann S, Kenner L, Rülicke T, Dong A, Ravichandran M, Brown PJ, Audette GF, Rauscher S, Dhe-Paganon S, Moriggl R, Gunning PT.

Nat Commun. 2019 Jun 7;10(1):2517. doi: 10.1038/s41467-019-10422-7.

13.

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.

Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R.

Haematologica. 2020 Jan 31;105(2):435-447. doi: 10.3324/haematol.2019.216986. Print 2020.

14.

STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia.

Klein K, Witalisz-Siepracka A, Maurer B, Prinz D, Heller G, Leidenfrost N, Prchal-Murphy M, Suske T, Moriggl R, Sexl V.

Leukemia. 2019 Sep;33(9):2336-2340. doi: 10.1038/s41375-019-0471-3. Epub 2019 Apr 9. No abstract available.

15.

Constitutive STAT5 activation regulates Paneth and Paneth-like cells to control Clostridium difficile colitis.

Liu R, Moriggl R, Zhang D, Li H, Karns R, Ruan HB, Niu H, Mayhew C, Watson C, Bangar H, Cha SW, Haslam D, Zhang T, Gilbert S, Li N, Helmrath M, Wells J, Denson L, Han X.

Life Sci Alliance. 2019 Apr 4;2(2). pii: e201900296. doi: 10.26508/lsa.201900296. Print 2019 Apr.

16.

Cell Metabolism Control Through O-GlcNAcylation of STAT5: A Full or Empty Fuel Tank Makes a Big Difference for Cancer Cell Growth and Survival.

Rauth M, Freund P, Orlova A, Grünert S, Tasic N, Han X, Ruan HB, Neubauer HA, Moriggl R.

Int J Mol Sci. 2019 Feb 27;20(5). pii: E1028. doi: 10.3390/ijms20051028. Review.

17.

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease.

Kosack L, Wingelhofer B, Popa A, Orlova A, Agerer B, Vilagos B, Majek P, Parapatics K, Lercher A, Ringler A, Klughammer J, Smyth M, Khamina K, Baazim H, de Araujo ED, Rosa DA, Park J, Tin G, Ahmar S, Gunning PT, Bock C, Siddle HV, Woods GM, Kubicek S, Murchison EP, Bennett KL, Moriggl R, Bergthaler A.

Cancer Cell. 2019 Jan 14;35(1):125-139.e9. doi: 10.1016/j.ccell.2018.11.018.

18.

Interplay of transcription factors STAT3, STAT1 and AP-1 mediates activity of the matrix metallo-proteinase-1 promoter in colorectal carcinoma cells.

Muller A, Gasch J, Albring KF, Aberger F, Nivarthi H, Khemeri M, Moriggl R, Friedrich KH.

Neoplasma. 2019 May 23;66(3):357-366. doi: 10.4149/neo_2018_180731N560. Epub 2018 Dec 12.

PMID:
30569725
19.

Editorial: Cytokines in liver diseases.

Ilangumaran S, Moriggl R, Kalvakolanu DV.

Cytokine. 2019 Dec;124:154608. doi: 10.1016/j.cyto.2018.12.001. Epub 2018 Dec 16.

PMID:
30563739
20.

Crosstalk between inflammatory mediators and endoplasmic reticulum stress in liver diseases.

Duvigneau JC, Luís A, Gorman AM, Samali A, Kaltenecker D, Moriggl R, Kozlov AV.

Cytokine. 2019 Dec;124:154577. doi: 10.1016/j.cyto.2018.10.018. Epub 2018 Nov 14.

PMID:
30446215
21.

High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype.

Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J.

Transl Oncol. 2019 Feb;12(2):256-268. doi: 10.1016/j.tranon.2018.10.010. Epub 2018 Nov 12. Erratum in: Transl Oncol. 2020 Feb;13(2):490-492.

22.

Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.

Kleinegger F, Hofer E, Wodlej C, Golob-Schwarzl N, Birkl-Toeglhofer AM, Stallinger A, Petzold J, Orlova A, Krassnig S, Reihs R, Niedrist T, Mangge H, Park YN, Thalhammer M, Aigelsreiter A, Lax S, Garbers C, Fickert P, Rose-John S, Moriggl R, Rinner B, Haybaeck J.

Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):308-321. doi: 10.1016/j.bbadis.2018.11.006. Epub 2018 Nov 9.

23.

Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression.

Kaltenecker D, Themanns M, Mueller KM, Spirk K, Suske T, Merkel O, Kenner L, Luís A, Kozlov A, Haybaeck J, Müller M, Han X, Moriggl R.

Cytokine. 2019 Dec;124:154569. doi: 10.1016/j.cyto.2018.10.010. Epub 2018 Oct 30.

24.

STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice.

Kaltenecker D, Themanns M, Mueller KM, Spirk K, Golob-Schwarzl N, Friedbichler K, Kenner L, Haybaeck J, Moriggl R.

Cytokine. 2019 Dec;124:154573. doi: 10.1016/j.cyto.2018.10.014. Epub 2018 Oct 28.

25.

Correction: The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.

Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knösel T, Kenner L, Freund P, Aberger F, Han X, Kralovics R, Dolznig H, Jennek S, Friedrich K, Moriggl R.

Oncotarget. 2018 Sep 18;9(73):33865. doi: 10.18632/oncotarget.26156. eCollection 2018 Sep 18.

26.

Life Under Hypoxia Lowers Blood Glucose Independently of Effects on Appetite and Body Weight in Mice.

Abu Eid S, Hackl MT, Kaplanian M, Winter MP, Kaltenecker D, Moriggl R, Luger A, Scherer T, Fürnsinn C.

Front Endocrinol (Lausanne). 2018 Aug 28;9:490. doi: 10.3389/fendo.2018.00490. eCollection 2018.

27.

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O.

Leukemia. 2019 Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. Epub 2018 Aug 21.

PMID:
30131584
28.

Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.

Valent P, Büsche G, Theurl I, Uras IZ, Germing U, Stauder R, Sotlar K, Füreder W, Bettelheim P, Pfeilstöcker M, Oberbauer R, Sperr WR, Geissler K, Schwaller J, Moriggl R, Béné MC, Jäger U, Horny HP, Hermine O.

Haematologica. 2018 Oct;103(10):1593-1603. doi: 10.3324/haematol.2018.192518. Epub 2018 Aug 3. Review.

29.

Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Jan Pencik, Pham HTT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DNT, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2018 Jul 23;9(8):800. doi: 10.1038/s41419-018-0773-9.

30.

Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma.

Sternberg C, Gruber W, Eberl M, Tesanovic S, Stadler M, Elmer DP, Schlederer M, Grund S, Roos S, Wolff F, Kaur S, Mangelberger D, Lehrach H, Hache H, Wierling C, Laimer J, Lackner P, Wiederstein M, Kasper M, Risch A, Petzelbauer P, Moriggl R, Kenner L, Aberger F.

Int J Cancer. 2018 Dec 1;143(11):2943-2954. doi: 10.1002/ijc.31724. Epub 2018 Oct 1.

31.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
32.

A haunted beast: Targeting STAT5BN642H in T-Cell Neoplasia.

Pham HTT, Hengstschläger M, Moriggl R.

Mol Cell Oncol. 2018 Mar 28;5(3):e1435181. doi: 10.1080/23723556.2018.1435181. eCollection 2018.

33.

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.

Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, Müller M, Moriggl R.

Leukemia. 2018 Aug;32(8):1713-1726. doi: 10.1038/s41375-018-0117-x. Epub 2018 Mar 27. Review.

34.

NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.

Seidi K, Jahanban-Esfahlan R, Monhemi H, Zare P, Minofar B, Daei Farshchi Adli A, Farajzadeh D, Behzadi R, Mesgari Abbasi M, Neubauer HA, Moriggl R, Zarghami N, Javaheri T.

Oncogene. 2018 Jul;37(29):3967-3980. doi: 10.1038/s41388-018-0213-4. Epub 2018 Apr 17.

35.

Pharmacologic inhibition of STAT5 in acute myeloid leukemia.

Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau CH, Sadovnik I, Bajusz D, Keserű GM, Grebien F, Kubicek S, Valent P, Gunning PT, Moriggl R.

Leukemia. 2018 May;32(5):1135-1146. doi: 10.1038/s41375-017-0005-9. Epub 2018 Feb 2.

36.

Tumor target amplification: Implications for nano drug delivery systems.

Seidi K, Neubauer HA, Moriggl R, Jahanban-Esfahlan R, Javaheri T.

J Control Release. 2018 Apr 10;275:142-161. doi: 10.1016/j.jconrel.2018.02.020. Epub 2018 Feb 16. Review.

PMID:
29454742
37.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M.

Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.

38.

AKT3 drives adenoid cystic carcinoma development in salivary glands.

Zboray K, Mohrherr J, Stiedl P, Pranz K, Wandruszka L, Grabner B, Eferl R, Moriggl R, Stoiber D, Sakamoto K, Wagner KU, Popper H, Casanova E, Moll HP.

Cancer Med. 2018 Feb;7(2):445-453. doi: 10.1002/cam4.1293. Epub 2017 Dec 28.

39.

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P.

Leukemia. 2018 Apr;32(4):1016-1022. doi: 10.1038/leu.2017.338. Epub 2017 Nov 29.

40.

The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone.

Eigner K, Filik Y, Mark F, Schütz B, Klambauer G, Moriggl R, Hengstschläger M, Stangl H, Mikula M, Röhrl C.

Sci Rep. 2017 Dec 13;7(1):17498. doi: 10.1038/s41598-017-17888-9.

41.

STAT5BN642H is a driver mutation for T cell neoplasia.

Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R.

J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/JCI94509. Epub 2017 Dec 4.

42.

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.

Orlova A, Wingelhofer B, Neubauer HA, Maurer B, Berger-Becvar A, Keserű GM, Gunning PT, Valent P, Moriggl R.

Expert Opin Ther Targets. 2018 Jan;22(1):45-57. doi: 10.1080/14728222.2018.1406924. Epub 2017 Nov 24. Review.

43.

Erratum. Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and HFD-Induced Obesity and Impairs the Feeding-Fasting Transition. Diabetes 2017;66:272-286.

Mueller KM, Hartmann K, Kaltenecker D, Vettorazzi S, Bauer M, Mauser L, Amann S, Jall S, Fischer K, Esterbauer H, Müller TD, Tschöp MH, Magnes C, Haybaeck J, Scherer T, Bordag N, Tuckermann JP, Moriggl R.

Diabetes. 2018 Feb;67(2):343-344. doi: 10.2337/db18-er02a. Epub 2017 Nov 16. No abstract available.

44.

Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation.

Kinslechner K, Schörghofer D, Schütz B, Vallianou M, Wingelhofer B, Mikulits W, Röhrl C, Hengstschläger M, Moriggl R, Stangl H, Mikula M.

Mol Cancer Res. 2018 Jan;16(1):135-146. doi: 10.1158/1541-7786.MCR-17-0292. Epub 2017 Oct 3.

45.

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB.

Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.

PMID:
28972014
46.

Human stem cells alter the invasive properties of somatic cells via paracrine activation of mTORC1.

Rosner M, Pham HTT, Moriggl R, Hengstschläger M.

Nat Commun. 2017 Sep 19;8(1):595. doi: 10.1038/s41467-017-00661-x.

47.

When the guardian sleeps: Reactivation of the p53 pathway in cancer.

Merkel O, Taylor N, Prutsch N, Staber PB, Moriggl R, Turner SD, Kenner L.

Mutat Res. 2017 Jul;773:1-13. doi: 10.1016/j.mrrev.2017.02.003. Epub 2017 Feb 17. Review.

PMID:
28927521
48.

Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.

Edlinger L, Berger-Becvar A, Menzl I, Hoermann G, Greiner G, Grundschober E, Bago-Horvath Z, Al-Zoughbi W, Hoefler G, Brostjan C, Gille L, Moriggl R, Spittler A, Sexl V, Hoelbl-Kovacic A.

Br J Haematol. 2017 Oct;179(2):229-241. doi: 10.1111/bjh.14833. Epub 2017 Jul 14.

49.

A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.

Sackmann Sala L, Boutillon F, Menara G, De Goyon-Pélard A, Leprévost M, Codzamanian J, Lister N, Pencik J, Clark A, Cagnard N, Bole-Feysot C, Moriggl R, Risbridger GP, Taylor RA, Kenner L, Guidotti JE, Goffin V.

J Pathol. 2017 Sep;243(1):51-64. doi: 10.1002/path.4924. Epub 2017 Jul 28.

PMID:
28603917
50.

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P.

Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8.

Supplemental Content

Loading ...
Support Center